The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

The Leeds Teaching Hospitals NHS Trust20 enrolled

Overview

The diagnosis of Arrhythmogenic right ventricular cardiomyopathy can be difficult. The 80 lead ECG may increase the specificity and sensitivity in diagnosing this potentially life threatening inherited cardiac condition. This pilot would form the basis of a much larger clinical trial to test the utility of this novel diagnostic tool.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Arrhythmogenic Right Ventricular Cardiomyopathy

Interventions

80 lead ECGDEVICE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a confirmed diagnosis of arrhythmogenic right ventricular cardiomyopathy who are being followed up in the cardiology clinic Exclusion Criteria: * Inability to consent * Pacing dependent patients * Other concomitant cardiag disease e.g. coronary artery disease * Atrial fibrillation

Outcomes

Primary Outcomes

QRS wave dispersion in an ECG

The difference in QRS wave dispersion between the right and left ventricular leads

Time frame: 5 minutes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.